The collaboration includes the initial validation and deployment of Ibex Prostate within HNL Lab Medicine’s LDT workflow.

A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, "Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation ...

MRI-Invisible Prostate Lesions: Are They Dangerous? MRI-invisible lesions are real. Experts debate what these lesions really mean for patient outcomes and care. Medscape Medical News, January 08, 2025 ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Prostate cancer is the second most common cancer in men, and almost 300,000 individuals are diagnosed with it each year in the U.S. To develop a consistent method of estimating prostate cancer size, ...

Brachytherapy and proton therapy are radiation therapies, while HIFU and TULSA are focal therapies with distinct mechanisms. Medicare typically covers HIFU but not TULSA, with potential future ...

Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy. Prevalence of treatment-acquired homozygous ...

Upon reviewing repeated prostate cancer screenings, researchers observed the absence of suspicious MRI findings in over 86% of men who had prostate-specific antigen (PSA) levels of 3 ng/mL or higher ...

Prostate cancer is one of the most common malignancies affecting men globally, usually developing within the prostate gland. While in its early stages, the disease is often confined to the gland ...